Olema Pharmaceuticals, Inc.
No SEC Form 4 filings for $OLMA in the last 30 days.
See all $OLMA insider activity →Olema Pharmaceuticals' stock fell 15.1% to $8.68 after AstraZeneca's SERD trial failure, raising concerns about Olema's similar drug. Stifel cut its price target to $30 from $48. The broader market decline also impacted biotech stocks.
Olema Pharmaceuticals, Inc. (OLMA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer SAN FRANCISCO, August 13, 2026 (Globe NewsWire) – Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen
Olema Pharmaceuticals, Inc. (OLMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Olema Oncology Reports Second Quarter 2026 Financial and Operating Results • Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027 • Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO
Over the past 7 days, AlphAI's AI scored 1 news story mentioning OLMA (Olema Pharmaceuticals, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent OLMA coverage spans financial news, corporate actions and market movers.
Negative clinical news and analyst target cut likely pressure OLMA lower in the near term.
The filing is primarily an executive-compensation and onboarding disclosure, with limited direct implications for near-term fundamentals.
Near-term catalyst shifts to Q1 2027 OPERA-01 top-line timing, while the Bayer collaboration expands OP-3136’s clinical optionality in mCRPC.
Routine insider selling via open-market sale, with no 10b5-1 plan disclosed, may modestly affect near-term sentiment but is not a fundamental catalyst.
The stock’s narrative is tied to a specific pivotal trial readout; positioning may build ahead of the fall timeframe.
AlphAI scores every news story that mentions OLMA with an AI model for sentiment and relevance, and aggregates insider trades from Olema Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Olema Pharmaceuticals' stock fell 15.1% to $8.68 after AstraZeneca's SERD trial failure, raising concerns about Olema's similar drug. Stifel cut its price target to $30 from $48. The broader market decline also impacted biotech stocks.
2 min readOlema Pharmaceuticals, Inc. (OLMA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer SAN FRANCISCO, August 13, 2026 (Globe NewsWire) – Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen
4 min readOlema Pharmaceuticals, Inc. (OLMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Olema Oncology Reports Second Quarter 2026 Financial and Operating Results • Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027 • Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO
6 min readHarmon Cyrus sold 25,000 shares of Olema Pharmaceuticals, Inc. (OLMA) at an average of $11.65 ($11.58–$11.71, $0.29M total) across 2 trades over 2026-07-23 to 2026-07-24.
2 min readJPMorgan analyst Anupam Rama named BridgeBio (BBIO), ORIC (ORIC) and Olema (OLMA) as top US SMid biotech picks, citing near-term catalysts and valuation. For BBIO, JPMorgan targets mid-$8–$9 on Attruby momentum and pipeline approvals; for ORIC, it highlights rinzimetostat dose-optimization and expects MEVPRO-1 data in 2H 2026; for OLMA, it points to fall OPERA-01 palazestrant readout.
4 min readOlema Pharmaceuticals, Inc. (OLMA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001750284 0001750284 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,
2 min readOlema Pharmaceuticals (NASDAQ:OLMA) reported initial Phase 1 data for OP-3136, its KAT6 inhibitor, at the 2026 ASCO Annual Meeting on May 21. The company said monotherapy was well tolerated, with no dose-limiting toxicities or treatment-related discontinuations, and showed anti-tumor activity across multiple solid tumors. Olema’s palazestrant Phase 3 OPERA-01 topline data is expected in fall 2026; OPERA-02 enrollment continues. It reported $505.3M cash at Q1 end.
4 min readSwedbank AB disclosed a new position in Olema Pharmaceuticals (NASDAQ:OLMA), buying 55,100 shares for about $1.38 million in Q4, raising its stake to 0.08%. Other filings show Jennison Associates, Kingdon Capital, Ameriprise, Candriam and Vanguard also adjusted holdings. Olema reported Q1 EPS of -$0.52 on May 12.
4 min readOlema Pharmaceuticals director Raman Prakash has been granted 27,061 stock options as equity compensation, with an exercise price of $14.59 per share, expiring on April 27, 2036. The options vest based on continuous service, with one portion vesting in full on June 11, 2026, and another in 36 equal monthly installments starting April 28, 2026. This transaction reflects compensation rather than open-market purchases.
2 min readOlema Pharmaceuticals CEO Sean Bohen provided updates on the company's pipeline, including an expected Fall readout for the OPERA-01 trial of palazestrant and Q2 2026 data for the KAT6 inhibitor OP-3136. Bohen also addressed the departure of CFO/COO Shane Kovacs, framing it as the company prepares for potential commercialization of palazestrant in the U.S. and seeks ex-U.S. partners. He emphasized palazestrant's potential as a best-in-class oral SERD, citing its pharmacologic attributes and past clinical results.
4 min read
